VacZine Analytics  
MarketVIEW: TBE vaccines

Published: October 2020

Tick-borne encephalitis (TBE) virus is the causative agent of tick-borne encephalitis (TBE), a potentially fatal neurological infection. The virus is transmitted to humans through the bite of infected Ixodes tick species which are endemic to a large area stretching from Southern Germany, across Russia to the islands of Northern Japan. Inactivated whole virus vaccines are licensed in Europe to prevent TBE and given to populations at risk in various countries. The main TBE vaccines are marketed by GSK vaccines (previously Novartis/Chiron) now divested as ‘Encepur’ to Bavarian Nordic (October 2019) and ‘FSME-immune’ or TicoVac, Pfizer Vaccines (previously Baxter vaccines). Russian local companies also produce TBE vaccines.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of TBE vaccines across endemic markets to 2035. The model contains value ($ m) and volume (mio doses) predictions for each country and discusses current dynamics in disease incidence and possible market upside scenarios.

THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf) + MS Excel MODEL (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV022 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. Please allow 2-3 weeks for report delivery. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains